139 related articles for article (PubMed ID: 37158934)
21. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis.
Dai Q; Wang Y; Liao M; Chen H
Ann Palliat Med; 2022 Dec; 11(12):3727-3742. PubMed ID: 36635998
[TBL] [Abstract][Full Text] [Related]
22. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
23. Local-regional control of recurrent breast carcinoma after mastectomy: does hyperfractionated accelerated radiotherapy improve local control?
Ballo MT; Strom EA; Prost H; Singletary SE; Theriault RL; Buchholz TA; McNeese MD
Int J Radiat Oncol Biol Phys; 1999 Apr; 44(1):105-12. PubMed ID: 10219802
[TBL] [Abstract][Full Text] [Related]
24. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
26. CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care.
Hui R; de Boer R; Lim E; Yeo B; Lynch J
Asia Pac J Clin Oncol; 2021 Jan; 17 Suppl 1():3-14. PubMed ID: 33506626
[TBL] [Abstract][Full Text] [Related]
27. Response to First-line Recurrence Treatment Influences Survival in Hormone Receptor-positive, HER2-negative Breast Cancer: A Multicenter Study.
Yamamura J; Kamigaki S; Tsujie M; Fujita J; Osato H; Higashi C; Kanaizumi H; Tanaka Y; Hamada M; Shinzaki W; Hashimoto Y; Komoike Y
In Vivo; 2019; 33(1):281-287. PubMed ID: 30587637
[TBL] [Abstract][Full Text] [Related]
28. Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature.
Ihnenfeld Arciénega I; Imesch P; Fink D; Dedes KJ
Target Oncol; 2015 Jun; 10(2):297-301. PubMed ID: 25511015
[TBL] [Abstract][Full Text] [Related]
29. A solitary brain metastasis as the only site of recurrence of HR positive, HER2 negative breast cancer: a case report and review of the literature.
Patel SH; Saito YD; Li Z; Ramaswamy B; Stiff A; Kassem M; Wesolowski R
J Med Case Rep; 2021 Jan; 15(1):4. PubMed ID: 33407851
[TBL] [Abstract][Full Text] [Related]
30. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
Sammons S; Shastry M; Dent S; Anders C; Hamilton E
Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
[TBL] [Abstract][Full Text] [Related]
31. Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial.
Peuker CA; Yaghobramzi S; Grunert C; Keilholz L; Gjerga E; Hennig S; Schaper S; Na IK; Keller U; Brucker S; Decker T; Fasching P; Fehm T; Janni W; Kümmel S; Schneeweiss A; Schuler M; Lüftner D; Busse A
Eur J Cancer; 2022 Feb; 162():45-55. PubMed ID: 34953442
[TBL] [Abstract][Full Text] [Related]
32. Local recurrence of mammary Paget's disease after nipple-sparing mastectomy and implant breast reconstruction: a case report and literature review.
Pu Q; Zhao Q; Gao D
World J Surg Oncol; 2022 Sep; 20(1):285. PubMed ID: 36064544
[TBL] [Abstract][Full Text] [Related]
33. Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study.
Davie A; Cuyun Carter G; Rider A; Bailey A; Lewis K; Price G; Ostojic H; Ringeisen F; Pivot X
ESMO Open; 2021 Aug; 6(4):100226. PubMed ID: 34371379
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.
Smith I; Robertson J; Kilburn L; Wilcox M; Evans A; Holcombe C; Horgan K; Kirwan C; Mallon E; Sibbering M; Skene A; Vidya R; Cheang M; Banerji J; Morden J; Sidhu K; Dodson A; Bliss JM; Dowsett M
Lancet Oncol; 2020 Nov; 21(11):1443-1454. PubMed ID: 33152284
[TBL] [Abstract][Full Text] [Related]
35. Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting.
Abdel-Razeq H; Sharaf B
Drug Des Devel Ther; 2022; 16():727-735. PubMed ID: 35321498
[TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
Han Y; Wang J; Wang Z; Xu B
Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
[TBL] [Abstract][Full Text] [Related]
37. Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Prowell TM; Bloomquist E; Tang S; Wedam SB; Royce M; Krol D; Osgood C; Ison G; Sridhara R; Pazdur R; Beaver JA; Amiri-Kordestani L
Lancet Oncol; 2021 Nov; 22(11):1573-1581. PubMed ID: 34656225
[TBL] [Abstract][Full Text] [Related]
38. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
[TBL] [Abstract][Full Text] [Related]
39. The effect and safety of CDK4/6 inhibitors combined endocrine therapy on HR+, HER2-breast cancer: a meta-analysis of randomized controlled trials.
Huang T; He Y; Yu C; Mao F; Si Y
Endokrynol Pol; 2023; 74(1):89-105. PubMed ID: 36704980
[TBL] [Abstract][Full Text] [Related]
40. Frequency of Immune Cell Subtypes in Peripheral Blood Correlates With Outcome for Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy.
Lafrenie RM; Speigl L; Buckner CA; Pawelec G; Conlon MS; Shipp C
Clin Breast Cancer; 2019 Dec; 19(6):433-442. PubMed ID: 31383605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]